{
    "Symbol": "NVO",
    "AssetType": "Common Stock",
    "Name": "Novo Nordisk A/S",
    "Description": "Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.",
    "CIK": "353278",
    "Exchange": "NYSE",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "PHARMACEUTICAL PREPARATIONS",
    "Address": "NOVO ALLE DK 2880, BAGSVAERD DENMARK, DK",
    "OfficialSite": "https://www.novonordisk.com",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2024-09-30",
    "MarketCapitalization": "386759655000",
    "EBITDA": "127400698000",
    "PERatio": "29.54",
    "PEGRatio": "1.287",
    "BookValue": "27.07",
    "DividendPerShare": "9.9",
    "DividendYield": "0.0168",
    "EPS": "2.92",
    "RevenuePerShareTTM": "60.7",
    "ProfitMargin": "0.35",
    "OperatingMarginTTM": "0.474",
    "ReturnOnAssetsTTM": "0.215",
    "ReturnOnEquityTTM": "0.887",
    "RevenueTTM": "270583005000",
    "GrossProfitTTM": "148506000000",
    "DilutedEPSTTM": "2.92",
    "QuarterlyEarningsGrowthYOY": "0.224",
    "QuarterlyRevenueGrowthYOY": "0.214",
    "AnalystTargetPrice": "114.68",
    "AnalystRatingStrongBuy": "2",
    "AnalystRatingBuy": "5",
    "AnalystRatingHold": "2",
    "AnalystRatingSell": "1",
    "AnalystRatingStrongSell": "1",
    "TrailingPE": "29.54",
    "ForwardPE": "22.03",
    "PriceToSalesRatioTTM": "1.429",
    "PriceToBookRatio": "23.03",
    "EVToRevenue": "10.31",
    "EVToEBITDA": "20.47",
    "Beta": "0.165",
    "52WeekHigh": "147.59",
    "52WeekLow": "81.5",
    "50DayMovingAverage": "102.02",
    "200DayMovingAverage": "123.53",
    "SharesOutstanding": "3366470000",
    "DividendDate": "2024-08-26",
    "ExDividendDate": "2024-08-16"
}